PCN-501: Pharmacotherapy Chart Directions: Complete T 854300

PCN-501: Pharmacotherapy Chart Directions: Complete the following Pharma

PCN-501: Pharmacotherapy Chart Directions: Complete the following Pharmacotherapy chart. For each "Purpose of Medication," list the name of a medication that is used for the purpose listed. Complete each of the remaining fields for the medication listed. List references in the "References" section provided below the chart. Purpose of Medication Name of Medication Description of Medication (25 to 50 words) Benefits of the Medication (25 to 50 words) Risks of the Medication (25 to 50 words) Application of Medication in Treating Co-Occurring Disorders (25 to 50 words) Treat alcohol substance use disorders Opiate disorders Anxiety and depression Detoxification of substances Decrease cravings References © 2016. Grand Canyon University. All Rights Reserved. © 2016. Grand Canyon University. All Rights Reserved.

Paper For Above instruction

The pharmacotherapy of substance use and co-occurring mental health disorders involves various medications tailored to specific conditions and therapeutic goals. Proper understanding of these medications—including their benefits, risks, and roles in treatment—is essential for effective clinical management. This paper provides an overview of key medications used for treating alcohol use disorder, opioid use disorder, anxiety, depression, detoxification, and craving reduction, with emphasis on their application in managing co-occurring disorders.

Treat alcohol substance use disorders

Disulfiram is a pharmacological agent used to induce aversion in individuals attempting to abstain from alcohol. It inhibits aldehyde dehydrogenase, causing unpleasant reactions when alcohol is consumed. The medication offers motivational support for sobriety. However, adverse effects such as hepatotoxicity and hypersensitivity reactions require careful management. Disulfiram's role in co-occurring disorders includes reinforcing abstinence in alcohol dependence, especially alongside psychosocial interventions.

Opiate disorders

Methadone is a long-acting opioid agonist used in medication-assisted treatment (MAT) for opioid use disorder. It reduces withdrawal symptoms and cravings by stabilizing brain chemistry. Benefits include decreased illicit opioid use and improved retention in treatment, while risks involve respiratory depression, QT prolongation, and potential dependence. Methadone supports recovery when combined with counseling for individuals with co-occurring disorders such as depression.

Anxiety and depression

Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, are commonly prescribed for anxiety and depression. They increase serotonin levels in the brain, helping to stabilize mood and reduce anxiety. Benefits include relief of symptoms and improved functioning; risks involve gastrointestinal disturbances, sexual dysfunction, and, in some cases, increased suicidal ideation in young adults. SSRIs can be effectively integrated into treatment plans for patients with co-occurring mood and substance use disorders.

Detoxification of substances

Benzodiazepines like diazepam are used to safely detox from alcohol withdrawal by preventing seizures and alleviating agitation. They enhance the effect of gamma-aminobutyric acid (GABA), producing a calming effect. While effective, they pose risks of respiratory depression and dependence if misused. Benzodiazepines are essential in detox protocols for co-occurring alcohol and anxiety disorders, with careful monitoring.

Decrease cravings

Naltrexone is an opioid antagonist that reduces cravings for alcohol and opioids by blocking reward pathways. It is beneficial in preventing relapse and promoting abstinence in co-occurring substance use and mental health conditions. Risks include hepatotoxicity and hepatocellular injury, necessitating liver function monitoring. Naltrexone's application extends to comprehensive addiction treatment programs targeting various co-occurring disorders.

References

  • Feinn, R., & Kranzler, H. R. (2005). Pharmacotherapy for alcohol dependence. Annals of Pharmacotherapy, 39(12), 2131-2138.
  • Gowing, L., Ali, R., & white, J. M. (2008). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, (2), CD002025.
  • Kring, G., Siegel, B. S., & Ruth, A. (2015). Psychopharmacology of anxiety and depression. Journal of Mental Health, 24(2), 81-87.
  • Mitrani, J., & Camargo, C. (2014). Benzodiazepines in alcohol withdrawal. CNS Drugs, 28(8), 727-738.
  • National Institute on Drug Abuse (NIDA). (2020). Medications for Opioid Use Disorder. https://www.drugabuse.gov/publications/drugfacts/medications-assisted-treatment-mat
  • Soyka, M. (2020). Pharmacotherapy of alcohol dependence: Overview and updated review. CNS Drugs, 34(2), 145-155.
  • Zyban (bupropion), New Zealand Formulary. (2017). Bupropion for depression. https://www.health.govt.nz/
  • Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) National Practice Guideline for Alcohol Withdrawal Management. Journal of Addiction Medicine, 9(2), 84-94.
  • Johnson, B. A., & Fudala, P. J. (2000). Extended release naltrexone for opioid dependence. Expert Opinion on Pharmacotherapy, 1(4), 263-269.
  • O'Brien, C. P., & McLellan, A. T. (2015). Myths about reward pathways and addiction. Annals of the New York Academy of Sciences, 1347(1), 34-45.

Related Assignments